Sivelestat sodium hydrate + Sivelestat sodium hydrate
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Lung Injury
Conditions
Acute Lung Injury, Systemic Inflammatory Response Syndrome
Trial Timeline
Jun 1, 2004 → —
NCT ID
NCT00219375About Sivelestat sodium hydrate + Sivelestat sodium hydrate
Sivelestat sodium hydrate + Sivelestat sodium hydrate is a approved stage product being developed by Ono Pharmaceutical for Acute Lung Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT00219375. Target conditions include Acute Lung Injury, Systemic Inflammatory Response Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lung Injury were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00219375 | Approved | Completed |
Competing Products
20 competing products in Acute Lung Injury